#HVO hVIVO PLC – £3.2m hLAB project January 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hLAB, the Group’s standalone virology and immunology laboratory service provider, has signed a new £2.7m contract with a US-based biotechnology client bringing the total value of this project to date to £3.2m.   As part of this new contract, hLAB will act as the only contracted virology…

Continue reading

#VELA investee #CDT Conduit Pharmaceuticals – Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub March 13, 2024 – Posted in: Vela Technologies Plc (VELA)

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”) today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of a robust intellectual property portfolio. The laboratory…

Continue reading

#HVO hVIVO PLC – Plans for a new larger state-of-the-art facility August 29, 2023 – Posted in: Blog, hVIVO (HVO)

·    Capacity increase to 50 quarantine beds with optionality to expand to 70 ·    Expansion of laboratory services to include cutting edge labs ·    Largely funded by multiple hVIVO clients hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its plans for a new consolidated facility at the fast-growing life sciences hub in Canary Wharf, London. The expansion, largely funded by hVIVO…

Continue reading